Literature DB >> 1719559

Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states.

D J Schneider1, B E Sobel.   

Abstract

Accelerated atherosclerosis accompanying diabetes mellitus, obesity, and some types of hypertension has been associated with hyperinsulinemia, augmented plasma plasminogen activator inhibitor type 1 (PAI-1), or both. We hypothesized that insulin and insulin-like growth factor type I (IGF-I) can influence synthesis of PAI-1, thereby potentially attenuating fibrinolysis. In HepG2 cells used as a model system, concentrations of insulin and IGF-I consistent with those seen in plasma independently stimulated PAI-1 synthesis. Accumulation of PAI-1 protein in conditioned medium over 24 hr was stimulated more with insulin alone than with the combination. Synergistic increases were evident, however, in the accumulation of PAI-1 protein over 48 hr with a concomitant increase in PAI-1 mRNA. A 10- to 20-fold increase in IGF binding protein I mRNA was seen 16-48 hr after exposure of the HepG2 cells to insulin and IGF-I, an increase abolished by cycloheximide. The results obtained are consistent with the hypothesis that hyperinsulinemia coupled with physiologic concentrations of IGF-I may attenuate fibrinolytic activity in vivo, thereby contributing to accelerated atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719559      PMCID: PMC52846          DOI: 10.1073/pnas.88.22.9959

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Serum IRI in insulin-treated diabetics during a 24-hour period.

Authors:  S M Rasmussen; L G Heding; E Parbst; A Volund
Journal:  Diabetologia       Date:  1975-04       Impact factor: 10.122

2.  Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.

Authors:  B S Knudsen; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

3.  Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.

Authors:  C L Lucore; B E Sobel
Journal:  Circulation       Date:  1988-03       Impact factor: 29.690

4.  Insulin-like growth factor (IGF) binding protein complementary deoxyribonucleic acid from human HEP G2 hepatoma cells: predicted protein sequence suggests an IGF binding domain different from those of the IGF-I and IGF-II receptors.

Authors:  Y L Lee; R L Hintz; P M James; P D Lee; J E Shively; D R Powell
Journal:  Mol Endocrinol       Date:  1988-05

5.  Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.

Authors:  K Landin; L Stigendal; E Eriksson; M Krotkiewski; B Risberg; L Tengborn; U Smith
Journal:  Metabolism       Date:  1990-10       Impact factor: 8.694

6.  Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.

Authors:  I Juhan-Vague; M C Alessi; P Joly; X Thirion; P Vague; P J Declerck; A Serradimigni; D Collen
Journal:  Arteriosclerosis       Date:  1989 May-Jun

7.  Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor.

Authors:  W E Hopkins; D R Westerhausen; B E Sobel; J J Billadello
Journal:  Nucleic Acids Res       Date:  1991-01-11       Impact factor: 16.971

8.  Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor.

Authors:  C L Lucore; S Fujii; T C Wun; B E Sobel; J J Billadello
Journal:  J Biol Chem       Date:  1988-11-05       Impact factor: 5.157

9.  Inhibition of insulin degradation by insulin-like growth factors I and II in human hepatoma (HepG2) cells.

Authors:  S Keller; C Schmid; J Zapf; E R Froesch
Journal:  Acta Endocrinol (Copenh)       Date:  1989-08

10.  Receptor-mediated endocytosis of tissue-type plasminogen activator by the human hepatoma cell line Hep G2.

Authors:  D A Owensby; B E Sobel; A L Schwartz
Journal:  J Biol Chem       Date:  1988-08-05       Impact factor: 5.157

View more
  18 in total

1.  Synergistic and multidimensional regulation of plasminogen activator inhibitor type 1 expression by transforming growth factor type β and epidermal growth factor.

Authors:  Xiaoling Song; Frederic W Thalacker; Marit Nilsen-Hamilton
Journal:  J Biol Chem       Date:  2012-02-10       Impact factor: 5.157

Review 2.  The Vasculature in Prediabetes.

Authors:  David H Wasserman; Thomas J Wang; Nancy J Brown
Journal:  Circ Res       Date:  2018-04-13       Impact factor: 17.367

Review 3.  Stabilization of high-risk plaques.

Authors:  Kohei Takata; Satoshi Imaizumi; Bo Zhang; Shin-Ichiro Miura; Keijiro Saku
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

4.  Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors:  Burton E Sobel; Regina M Hardison; Saul Genuth; Maria M Brooks; Robert D McBane; David J Schneider; Richard E Pratley; Kurt Huber; Robert Wolk; Ashok Krishnaswami; Robert L Frye
Journal:  Circulation       Date:  2011-07-18       Impact factor: 29.690

5.  Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice.

Authors:  F Samad; D J Loskutoff
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

6.  Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells.

Authors:  Kristin G Nørsett; Islay Steele; Cedric Duval; Stephen J Sammut; Senthil V M Murugesan; Susan Kenny; Lucille Rainbow; Rod Dimaline; Graham J Dockray; D Mark Pritchard; Andrea Varro
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-30       Impact factor: 4.052

Review 7.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

8.  Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population.

Authors:  J A Schoenhard; F W Asselbergs; K A Poku; S A Stocki; S Gordon; D E Vaughan; N J Brown; J H Moore; Scott M Williams
Journal:  Hum Genet       Date:  2008-10-25       Impact factor: 4.132

9.  Plasma insulinlike growth factor 1 and binding-protein 3 and risk of myocardial infarction in women: a prospective study.

Authors:  John H Page; Jing Ma; Michael Pollak; Joann E Manson; Susan E Hankinson
Journal:  Clin Chem       Date:  2008-08-14       Impact factor: 8.327

10.  Coronary capillary network remodeling and hypofibrinolysis in aged obese diabetic rats: implications for increased myocardial vulnerability to ischemia.

Authors:  Taeko Sugawara; Satoshi Fujii; A K M Tarikuz Zaman; Daisuke Goto; Tomoo Furumoto; Shogo Imagawa; Jie Dong; Ichiro Sakuma; Subrina Jesmin; Hiroko Togashi; Mitsuhiro Yoshioka; Tomiyasu Koyama; Akira Kitabatake
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.